Cargando…
Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine
Autores principales: | Jackson, Doreen, Qiao, Na, Greene, Julia M, Hale, Diane, Berry, John, Trappey, Alfred, Vreeland, Timothy, Clifton, Guy, Ibrahim, Nuhad, Toms, Annie, Peoples, George E, Mittendorf, Elizabeth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645458/ http://dx.doi.org/10.1186/2051-1426-3-S2-P156 |
Ejemplares similares
-
Preliminary results of the Phase IIa trial of a folate binding protein (FBP) adjuvant cancer vaccine (E39+GM-CSF) in ovarian and endometrial cancer patients to prevent recurrence
por: Greene, Julia, et al.
Publicado: (2014) -
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
por: Jackson, Doreen O., et al.
Publicado: (2016) -
Correlation of HER2/neu antibody response to clinical response in a Phase II trial of the ae37+gm-csf her2 peptide vaccine
por: Greene, Julia, et al.
Publicado: (2014) -
Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
por: Brown, Tommy A., et al.
Publicado: (2019) -
39e session du Conseil du CERN
Publicado: (1968)